Speciality Medicines

SPML

Q: How strong is Speciality Medicines balance sheet?

Balance sheet of Speciality Medicines is strong.It shouldn't have solvency or liquidity issues.

Q: Is the debt of Speciality Medicines increasing or decreasing?

Yes, The net debt of Speciality Medicines is increasing.Latest net debt of Speciality Medicines is ₹3.76 Crs as of Mar-25.This is greater than Mar-24 when it was ₹2.58 Crs.

Q: Is Speciality Medicines stock expensive?

There is insufficient historical data to gauge this.Latest PE of Speciality Medicines is 27.54

Price

Nano Cap

₹237 Cr.

New to Zerodha? Sign-up for free.

Speciality Medicines, established in February 2021, specializes in exporting, trading, and distributing pharmaceutical medicines and vaccines globally. The company is renowned for its high-quality an… More

Speciality Medicines, established in February 2021, specializes in exporting, trading, and distribu… More

Low

121

52W Range

High

381

27.54

Sector PE

29.86

P/B

Div.Yield

ROE

28.3%

EBIDTA

ROCE

27.73

EPS

New to Zerodha? Sign-up for free.

Get instant stock alerts

Share Price
Financials
Revenue mix
Shareholdings
Peers
Forensics

Coming soon

Summary
Profit & Loss
Balance sheet
Cashflow

Yearly | Quarterly

View Detailed Summary

This data is currently unavailable for this company.

Yearly | Quarterly

(In Cr.)

(In Cr.)
This data is currently unavailable for this company.

Financial Ratio's

(In %)

Detailed P&L Report

(In Cr.)

Detailed Balance Sheet

Financial Year (In Cr.)

Detailed Cash Flow

Product wise
Location wise

SPML
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

SPML
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

More Info

Shareholdings

Holders

Detailed Shareholdings

This data is currently unavailable for this company.

Peers

Detailed Peers

Forensics

View Detailed Forensics

Recent events

News
Corporate Actions

Speciality Medicines Finalizes Commercial Arrangement With International Entity

Apr 23, 2026

Speciality Medicines Finalizes Commercial Arrangement With International Entity

Apr 22, 2026

This data is currently unavailable for this company.

More Nano Cap Ideas

See similar 'Nano' cap companies with recent activity

Promoter Buying

Companies where the promoters are bullish

Detailed List

Capex

Companies investing on expansion

Detailed List

Superstar Investor

Companies where well known investors have invested

Detailed List

Popular questions

Business
Financials
Share Price
Shareholdings

What does Speciality Medicines do?

Speciality Medicines, incorporated in February 2021, is primarily focused on the export, trading, and distribution of pharmaceutical medicines and vaccines. The company is specialized in global supply of all medicinal products and a well-known distributor in the industry for providing quality rich, reliable services.

Who are the competitors of Speciality Medicines?

Speciality Medicines major competitors are Remus Pharmaceutical, Trident Lifeline, Mono Pharmacare. Market Cap of Speciality Medicines is ₹237 Crs. While the median market cap of its peers are ₹303 Crs.

Is Speciality Medicines financially stable compared to its competitors?

Speciality Medicines seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Does Speciality Medicines pay decent dividends?

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Speciality Medicines latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

How has Speciality Medicines allocated its funds?

Companies resources are allocated to majorly unproductive assets like Inventory, Short Term Loans & Advances

How strong is Speciality Medicines balance sheet?

Balance sheet of Speciality Medicines is strong. It shouldn't have solvency or liquidity issues.

Is the profitablity of Speciality Medicines improving?

Yes, profit is increasing. The profit of Speciality Medicines is ₹8.61 Crs for Mar 2025, ₹2.93 Crs for Mar 2024 and ₹1.69 Crs for Mar 2023

Is the debt of Speciality Medicines increasing or decreasing?

Yes, The net debt of Speciality Medicines is increasing. Latest net debt of Speciality Medicines is ₹3.76 Crs as of Mar-25. This is greater than Mar-24 when it was ₹2.58 Crs.

Is Speciality Medicines stock expensive?

There is insufficient historical data to gauge this. Latest PE of Speciality Medicines is 27.54

Has the share price of Speciality Medicines grown faster than its competition?

There is not enough historical data for the companies share price.

Is the promoter bullish about Speciality Medicines?

There is Insufficient data to gauge this.

Are mutual funds buying/selling Speciality Medicines?

There is Insufficient data to gauge this.

SPML

Share Price

Financials

Summary

Profit & Loss

Balance sheet

Cashflow

Revenue mix

Product wise

Location wise

Shareholdings

Peers

Forensics

Recent events

News

Corporate Actions

Speciality Medicines Finalizes Commercial Arrangement With International Entity

Speciality Medicines Finalizes Commercial Arrangement With International Entity

More Nano Cap Ideas

Promoter Buying

Capex

Superstar Investor

Popular questions

Business

Financials

Share Price

Shareholdings

What does Speciality Medicines do?

Who are the competitors of Speciality Medicines?

Is Speciality Medicines financially stable compared to its competitors?

Does Speciality Medicines pay decent dividends?

How has Speciality Medicines allocated its funds?

How strong is Speciality Medicines balance sheet?

Is the profitablity of Speciality Medicines improving?

Is the debt of Speciality Medicines increasing or decreasing?

Is Speciality Medicines stock expensive?

Has the share price of Speciality Medicines grown faster than its competition?

Is the promoter bullish about Speciality Medicines?

Are mutual funds buying/selling Speciality Medicines?